
    
      This is a phase I, dose-escalation study of Hsp90 inhibitor AUY922 followed by a phase II
      study. Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib
      hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression
      or unacceptable toxicity. After completion of study treatment, patients are followed up
      periodically.
    
  